Denali Therapeutics (DNLI) Projected to Announce Earnings on Tuesday

Denali Therapeutics (NASDAQ:DNLI) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.3222) per share and revenue of $12.22 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.15 million. During the same period last year, the company posted ($0.72) EPS. On average, analysts expect Denali Therapeutics to post ($2.70) EPS for the current fiscal year and ($2.45) EPS for the next fiscal year.

Denali Therapeutics Trading Down 0.4%

Shares of Denali Therapeutics stock traded down $0.08 on Tuesday, hitting $18.58. 45,792 shares of the company’s stock traded hands, compared to its average volume of 1,717,666. The firm’s 50-day moving average price is $21.09 and its two-hundred day moving average price is $21.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. The stock has a market capitalization of $2.97 billion, a PE ratio of -6.49 and a beta of 1.02. Denali Therapeutics has a one year low of $13.75 and a one year high of $27.30.

Analyst Upgrades and Downgrades

DNLI has been the subject of several analyst reports. Wedbush restated an “outperform” rating and set a $26.00 target price on shares of Denali Therapeutics in a research report on Monday, July 13th. Robert W. Baird set a $34.00 price objective on shares of Denali Therapeutics in a research report on Friday, August 7th. B. Riley Financial boosted their price objective on shares of Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 price objective for the company. Finally, Morgan Stanley raised their price target on shares of Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.85.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the transaction, the insider directly owned 278,995 shares of the company’s stock, valued at $6,539,642.80. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.